Medicine, Hematology Oncology Division

Grants

Grants per year 1995 2007 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2028

• 468 Active
• 1104 Finished

Grants per year

Search results

• Prot #INCB 24360-203: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 (Epacadostat) in Combination With MEDI4736 (Durvalumab) in Subjects With Selected Advanced Solid Tumors

  Matsangou, M.

  inVentiv Health Clinical, Incyte Corporation

  3/1/17 → 3/1/20

  Project: Research project

• Fas protects cancer stem cells from death

  Peter, M. E. & Murmann, A. E.

  National Cancer Institute

  3/1/15 → 2/29/20

  Project: Research project

  • Neoplastic Stem Cells 100%
  • Fas Ligand Protein 89%
  • Cell Death 71%
  • Neoplasms 49%
  • Apoptosis 23%

• Prot #APL-B-021-13: A Phase II Study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

  Pro, B.

  Pharma Mar, S.A. Sociedad Unipersonal

  2/28/17 → 2/28/20

  Project: Research project

• Prot #20100031: NU 16B09: A Phase II, Open label Study to evaluate Denosumab in patients with ER and/or PR-positive, HER2-negative Metastatic Breast Cancer (MBC) with bone metastases and detectable circulating tumor cells (CTCs)

  Jain, S.

  Amgen, Inc.

  2/23/17 → 2/23/20

  Project: Research project

• Prot #1315.2: An Open-Label, Phase I/II Trial To Determine The Maximum Tolerated Dose And Investigate Safety, Pharmacokinetics And Efficacy Of BI 836858 In Combination With Decitabine In Patients With Acute Myeloid Leukemia

  Altman, J. K.

  Boehringer Ingelheim Pharmaceuticals, Inc.

  2/13/17 → 2/13/20

  Project: Research project

• Prot #I5B-EW-JGDI: An Open-Label Study to Evaluate the Pharmacokinetics of Doxorubicin following the Concomitant Intravenous Administration of Olaratumab (IMC-3G3) to Patients with Advanced Soft Tissue Sarcoma

  Agulnik, M.

  Covance Inc., Eli Lilly and Company

  1/21/15 → 1/31/20

  Project: Research project

• Prot# X05211: A Phase II Trial of Combination Bortezomib and Rituximab as Front-Line Therapy for Low-Grade Non-Hodgkin's Lymphoma (NU Prot# NU 06H1)

  Gordon, L. I., Frankfurt, O., Kuzel, T. M., Mehta, J., Singhal, S. & Winter, J. N.

  Millennium Pharmaceuticals, Inc

  6/29/06 → 1/31/20

  Project: Research project

• An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer

  Matei, D. E.

  National Cancer Institute

  3/28/16 → 1/31/20

  Project: Research project

  • guadecitabine 100%
  • Epigenome 93%
  • Ovarian Neoplasms 73%
  • Platinum 65%
  • Carboplatin 58%

• Prot #MK-3475-183: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM).

  Singhal, S.

  Merck Sharp & Dohme Corporation

  1/26/17 → 1/26/20

  Project: Research project

• Fellowship in support of Andrew Volk: The role of CHAF1B in maintaining the undifferentiated state of myeloid leukemic stem cells

  Crispino, J. D.

  Leukemia & Lymphoma Society

  7/1/19 → 1/12/20

  Project: Research project

  • Acute Myeloid Leukemia 100%
  • Myeloid Progenitor Cells 85%
  • Down Syndrome Critical Region 72%
  • Down Syndrome 43%
  • Myeloid Cells 42%

• Melanoma Research Professor in Translational Medicine

  Sosman, J. A.

  American Cancer Society

  5/1/16 → 12/31/19

  Project: Research project

  • Melanoma 100%
  • Translational Medical Research 94%
  • Neoplasms 47%
  • Mutation 20%
  • Neoplasm Genes 20%

• Molecular mechanisms of relapse after therapy discontinuation in chronic myeloid leukemia

  Eklund, E. A. & Huang, W.

  American Society of Hematology

  7/1/18 → 12/31/19

  Project: Research project

  • Protein-Tyrosine Kinases 100%
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 86%
  • Recurrence 54%
  • Leukemia 29%
  • Stem Cells 26%

• Prot #MDV3100-12: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive a

  Gradishar, W. J.

  Medivation, Inc.

  11/8/13 → 12/31/19

  Project: Research project

• Survivorship Enhancement in men with prostate cancer At Risk for poor Cognitive Health during treatment with ADT (SEARCH)

  Morgans, A. K. & Wang, L.

  Prostate Cancer Foundation

  12/31/17 → 12/31/19

  Project: Research project

  • Androgens 100%
  • Prostatic Neoplasms 93%
  • Survivorship 91%
  • Cancer Survivors 43%
  • Health 36%

• ECOG/FSTRF PSA for ECOG Clinical Trial Protocols

  Benson III, A. B.

  Frontier Science and Technology Research Foundation, National Cancer Institute

  5/1/99 → 12/31/19

  Project: Research project

• Targeting pro-metastatic neutrophils to inhibit breast cancer metastasis

  Liu, X. & Cristofanilli, M.

  Susan G. Komen Breast Cancer Foundation

  9/12/18 → 12/31/19

  Project: Research project

  • Zileuton 100%
  • Hyperforin 49%
  • Block Like Crystal 39%
  • Progesterone 34%
  • Estrogen 31%

• SurvivorConcierge: Extending Cancer Survivorship Care Beyond the Clinic Using a Smartphone-enabled Monitoring, Navigation and Tailored Intervention Program

  Garcia, S. F., Bass, M., Jordan, N., Kircher, S. M., Penedo, F. J. & Segawa, E.

  Vignet Inc., National Cancer Institute

  9/15/15 → 12/31/19

  Project: Research project

  • Smartphone 100%
  • Patient-Centered Care 97%
  • Cancer Survivors 90%
  • Neoplasms 26%
  • Therapeutics 13%

• Prot #CD-ON-CAT-8015-1053: A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia

  Dinner, S. N.

  PRA Health Sciences, MedImmune, LLC

  11/14/14 → 12/30/19

  Project: Research project

• Molecular and clinical investigations to reduce the morbidity of prostate cancer

  Schaeffer, E. M., Abdulkadir, S. A. & Roh, M.

  Prostate Cancer Foundation, Canica AS

  12/1/16 → 12/21/19

  Project: Research project

• Prot #M14-361: A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer

  Chae, Y. K.

  AbbVie Inc.

  12/17/15 → 12/16/19

  Project: Research project

• Membrane-Cytoskeletal Remodeling in Platelet Biogenesis

  Eklund, E. A. & Quaggin, S. E.

  National Heart, Lung, and Blood Institute

  4/1/15 → 11/15/19

  Project: Research project

  • cdc42 GTP-Binding Protein 100%
  • Dynamins 92%
  • Blood Platelets 57%
  • Megakaryocytes 42%
  • Wiskott-Aldrich Syndrome Protein 40%

• Multi-Center Chart Review Study in the US to Examine Treatment Patterns and Associated Outcomes among Patients with Advance Neuroendocrine Tumors (NET) of Lung Origin

  Benson III, A. B.

  Analysis Group, Inc., Novartis Pharmaceuticals Corporation

  11/11/16 → 11/11/19

  Project: Research project

• Multi-Center Chart Review Study in the US to Examine Treatment Patterns and Associated Outcomes among Patients with Advanced Neuroendocrine Tumors (NET) of Gastrointestinal (GI) Origin

  Benson III, A. B.

  Analysis Group, Inc., Novartis Pharmaceuticals Corporation

  11/11/16 → 11/11/19

  Project: Research project

• Subproject for Training Program in Oncogenesis and Developmental Biology

  Eklund, E. A.

  National Cancer Institute

  9/24/14 → 10/31/19

  Project: Research project

  • education programs 100%
  • carcinogenesis 78%
  • Biological Sciences 61%
  • funding 59%
  • neoplasms 40%

• Training Program in Oncogenesis and Developmental Biology

  Eklund, E. A., Kiyokawa, H., LaBonne, C. & Leikin, R. G.

  National Cancer Institute

  9/24/14 → 10/31/19

  Project: Research project

  • education programs 100%
  • carcinogenesis 78%
  • Biological Sciences 61%
  • funding 59%
  • neoplasms 40%